Sanofi (NASDAQ:SNY) Shares Gap Down - Time to Sell?

Sanofi (NASDAQ:SNY - Get Free Report)'s share price gapped down before the market opened on Wednesday . The stock had previously closed at $48.94, but opened at $47.74. Sanofi shares last traded at $48.00, with a volume of 471,933 shares traded.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. StockNews.com cut Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Citigroup upgraded shares of Sanofi to a "strong-buy" rating in a report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $57.50.

Sanofi Stock Down 3.9 %

The company has a market capitalization of $119.30 billion, a PE ratio of 23.98, a P/E/G ratio of 1.23 and a beta of 0.58. The stock's fifty day moving average is $50.72 and its two-hundred day moving average is $52.09. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion for the quarter, compared to analysts' expectations of $16.59 billion. During the same period in the previous year, the company earned $2.55 earnings per share. The company's quarterly revenue was up 12.3% on a year-over-year basis. As a group, analysts predict that Sanofi will post 4.06 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. POM Investment Strategies LLC purchased a new stake in Sanofi during the second quarter valued at about $25,000. Northwest Investment Counselors LLC purchased a new stake in shares of Sanofi during the 3rd quarter valued at approximately $29,000. Concord Wealth Partners boosted its holdings in Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company's stock worth $34,000 after buying an additional 363 shares during the period. Arrow Financial Corp purchased a new position in Sanofi in the 2nd quarter valued at approximately $35,000. Finally, Fortitude Family Office LLC raised its holdings in Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company's stock valued at $43,000 after acquiring an additional 659 shares during the period. Hedge funds and other institutional investors own 14.04% of the company's stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.